Chemicals and intermediates used in pharmaceutical manufacturing and drug development.
chemXplore tracks 135 projects in pharma, of which 36 are active.
19 new construction, 16 expansion, and 1 revamp / retrofit.
3 of the active projects carry no start-up date yet.
Owners and developers: Evonik Industries AG (4), Lilly (3), Merck (3), Novo Nordisk (3), Eli Lilly and Company (2), Genentech, Inc. (2)
Investors: Eli Lilly and Company (2), European Investment Bank (2), Evonik Industries AG (2), Takeda (2), AGC Group (1), Clariant AG (1)
Contractors, licensors, and offtakers are recorded on 13 of these 36 projects For subscribers
Targeting: Orforglipron (5), Retatrutide (2), Coagulation factor IX (1), Fumed Silica (1), Glucagon-like peptide-1 (1), Isobutene (1)
evERA Phase III: giredestrant+everolimus doubled median PFS in ESR1‑mutated patients and improved ITT PFS; OS immature; manageable safety; FDA review dates set for Nov 30 and Dec 18, 2026.
Phase 2b trial met HiSCR50 at week 16 for two dosing regimens; HiSCR75 and DLQI showed numeric gains; safety comparable to placebo; results to inform Phase 3.
Combination achieved up to 23.3% weight loss (54.1 lbs) and 2.9% A1C reduction versus 14.8% (34.4 lbs) and 2.4% with tirzepatide; Phase 3 to start Q4 2026.
Investigational iPSC-derived cell therapy for primary photoreceptor diseases receives orphan status across multiple inherited retinal disorder indications; being tested in a Phase 1/2a trial.
Ro telehealth real-world data: mean 4.1% weight loss at three months; 40.7% reached ≥5% loss; obesity (BMI≥30) prevalence fell 21.6 percentage points; N=194.
Rapid, significant relief in skin clearance, itch, pain and patient satisfaction versus placebo; consistent safety and fewer patients required rescue medication.
Regulators and stakeholders agreed 10 priority actions to close research, trial and data gaps and improve inclusion of women across the medicines lifecycle, with a roadmap due by end-2026.
fMRI shows reduced ‘food noise’ and cravings; trials report major weight loss, reductions in abdominal/liver/pancreas fat and preliminary bone‑marker reassurance.
Wholly owned Korea subsidiary to secure marketing authorizations and build phased in‑house sales for pipeline drugs including sparsentan and NXT007.
Phase III data showed ARR reductions of 51% and 58% vs teriflunomide and a numerical 12% reduction in PPMS progression versus ocrelizumab; CNS‑penetrant, non‑covalent BTK inhibitor.
By country, the most active first. active / all projects
The 8 with the most active projects, of 26 countries.
